AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
This article was originally published in Scrip
AstraZeneca finally pulled off a US win for Brilinta (ticagrelor), with the FDA granting the OK on 20 July for the London drug maker to market the oral antiplatelet medicine as a therapy to reduce the rate of heart attack and cardiovascular death in adults with acute coronary syndrome (ACS) – an umbrella term for conditions that result from a reduction in blood flow to the heart muscle.
You may also be interested in...
HeartofType2 unbranded campaign is aimed at increasing awareness of CV disease in type 2 diabetics. FDA advisory committee strongly endorses new claim for the GLP-1 agonist but recommends limiting it to diabetics with established CV or chronic kidney disease.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.